GSK plc has reported strong real-world results for its RSV vaccine, showing major reductions in RSV-related hospitalizations and serious complications in adults aged 60 and older at RSVVW’26 in Rome.
Teva and Sanofi reveal duvakitug’s 44-week success, showing lasting remission in ulcerative colitis and Crohn’s patients, reinforcing TL1A as a promising treatment target.
Eli Lilly’s Retevmo delivers significant gains in event-free survival for early-stage RET fusion-positive NSCLC, marking a breakthrough in targeted lung cancer therapy.
Bharat Biotech is exploring a new biologics manufacturing facility near Chennai, aiming to produce advanced therapies including monoclonal antibodies and diabetes treatments as part of its long-term growth strategy.
Aurobindo Pharma aims for significant biosimilar growth by 2029, with approved oncology products and strategic plans for Europe and Latin America markets, says CEO Satakarni Makkapati.
AstraZeneca Pharma India has received CDSCO approval to import and market Imfinzi for an additional cancer indication, expanding treatment options for advanced and recurrent endometrial cancer patients in India.
Roche’s experimental drug, fenebrutinib, has successfully passed its late-stage trial, offering hope for patients with multiple sclerosis. The drug significantly reduced disease relapses, marking a critical milestone in MS treatment.
Fujifilm India today launched four new diagnostic imaging and healthcare IT solutions at IRIA 2026, highlighting its focus on AI-enabled systems, workflow efficiency, and wider access to advanced imaging across India.
Sanofi has reported positive phase 3 data for venglustat in type 3 Gaucher disease, showing meaningful neurological improvements and comparable non-neurological outcomes versus enzyme replacement therapy.
Sun Pharma Advanced Research Company has secured an FDA Priority Review Voucher tied to its neonatal seizure drug Sezaby, strengthening its regulatory position and offering strategic flexibility for future drug approvals.